3 results match your criteria: "Birla Institute of Technology and Science-Pilani Pilani Campus Pilani-333031 Rajasthan India murugesan@pilani.bits-pilani.ac.in.[Affiliation]"

Article Synopsis
  • A lot of people are getting metabolic syndrome, which can lead to a disease called non-alcoholic fatty liver disease (NAFLD) that happens when fat builds up in the liver.
  • Researchers looked for drugs that can stop an enzyme called SCD1, which helps create fat in the liver, using a special database and computer models.
  • They found that a drug called Montelukast seems to help lower fat in the liver and reduce damage caused by free radicals, suggesting it could be a good treatment for NAFLD.
View Article and Find Full Text PDF

Stearoyl-CoA desaturase 1 (SCD1) is one of the key enzymes involved in lipid metabolism, plays a vital role in the synthesis of monounsaturated fatty acids (MUFAs) from saturated fatty acids (SFAs). Due to its promising therapeutic potential in treating metabolic disorders, cancers, and skin diseases there is an increasing interest in the development of novel inhibitors against SCD1. This review comprehensively explores the evolution of potential SCD1 inhibitors, focusing on systemic and liver-targeted inhibitors and discusses their structure-activity relationship (SAR) pattern.

View Article and Find Full Text PDF

Isoquinoline alkaloids are a large group of natural products in which 1,2,3,4-tetrahydroisoquinolines (THIQ) form an important class. THIQ based natural and synthetic compounds exert diverse biological activities against various infective pathogens and neurodegenerative disorders. Due to these reasons, the THIQ heterocyclic scaffold has garnered a lot of attention in the scientific community which has resulted in the development of novel THIQ analogs with potent biological activity.

View Article and Find Full Text PDF